Evaluating the links between schizophrenia and sleep and circadian rhythm disruption by David Pritchett et al.
BIOLOGICAL PSYCHIATRY - REVIEW ARTICLE
Evaluating the links between schizophrenia and sleep
and circadian rhythm disruption
David Pritchett • Katharina Wulff • Peter L. Oliver •
David M. Bannerman • Kay E. Davies • Paul J. Harrison •
Stuart N. Peirson • Russell G. Foster
Received: 15 March 2012 / Accepted: 20 April 2012 / Published online: 10 May 2012
 The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract Sleep and circadian rhythm disruption (SCRD)
and schizophrenia are often co-morbid. Here, we propose
that the co-morbidity of these disorders stems from the
involvement of common brain mechanisms. We summarise
recent clinical evidence that supports this hypothesis,
including the observation that the treatment of SCRD leads
to improvements in both the sleep quality and psychiatric
symptoms of schizophrenia patients. Moreover, many
SCRD-associated pathologies, such as impaired cognitive
performance, are routinely observed in schizophrenia. We
suggest that these associations can be explored at a
mechanistic level by using animal models. Specifically, we
predict that SCRD should be observed in schizophrenia-
relevant mouse models. There is a rapidly accumulating
body of evidence which supports this prediction, as sum-
marised in this review. In light of these emerging data, we
highlight other models which warrant investigation, and
address the potential challenges associated with modelling
schizophrenia and SCRD in rodents. Our view is that an
understanding of the mechanistic overlap between SCRD
and schizophrenia will ultimately lead to novel treatment
approaches, which will not only ameliorate SCRD in
schizophrenia patients, but also will improve their broader
health problems and overall quality of life.
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Generation of circadian rhythms and sleep
Sleep and circadian rhythms are not synonymous. Circa-
dian rhythms are endogenous 24-h oscillations in physiol-
ogy and behaviour that enable an organism to anticipate
and adapt to the changing temporal demands of the envi-
ronment. An internal clock acts to coordinate the 24-h
rhythms of multiple cellular and organ systems within an
individual so that different aspects of physiology and
behaviour are appropriately synchronised to each other.
These rhythms arise from a sub-cellular transcriptional–
translational feedback loop (Fig. 1a), involving a number
of core clock genes (Lowrey and Takahashi 2011; Reppert
and Weaver 2002). In mammals, light is the primary time
cue (zeitgeber), which entrains the internal clock to the
external light environment. Light information is relayed
from the eyes to the primary circadian pacemaker located
in the suprachiasmatic nuclei (SCN) of the hypothalamus
(Moore 1973; Moore and Klein 1974), which in turn reg-
ulates physiology and behaviour. Additional oscillators are
found in tissues throughout the body, regulating local
physiology (Dibner et al. 2010).
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Whilst sleep/wake behaviour is perhaps the most obvi-
ous output of the circadian system, sleep biology involves
much more than the circadian system. In addition to a
circadian drive for wakefulness, sleep is under homeostatic
regulation, whereby an increased duration of wakefulness
leads to an increased need for sleep. The homeostatic drive
for sleep is the product of a complex network of brain
regions and neurotransmitter pathways (Fig. 1b), none of
which are exclusive to the generation of sleep (Tobler
1995). This complexity makes sleep very vulnerable to
disruption. Small changes in brain function can have a big
impact on sleep, and disrupted sleep leads to multiple
health problems (Table 1).
Sleep and circadian rhythm disruption (SCRD)
in schizophrenia
The relationship between schizophrenia and abnormal
sleep was first described in the late nineteenth century by
the German psychiatrist Emil Kraepelin (Manoach and
Stickgold 2009). Today, sleep and circadian rhythm dis-
ruption (SCRD) is reported in 30–80 % of patients with
schizophrenia, and is increasingly recognised as one of the
most common features of the disorder (Cohrs 2008). Sleep
disturbances in schizophrenia include increases in sleep
latency, and reductions in total sleep time, sleep efficiency,
REM sleep latency, REM sleep density and slow-wave
sleep duration (Cohrs 2008; Manoach and Stickgold 2009).
Schizophrenia is also associated with significant circadian
disruption, including the abnormal phasing, instability and
fragmentation of rest-activity rhythms (Martin et al. 2001,
2005; Wulff et al. 2006, 2009). Crucially, patients with
SCRD score badly on many quality-of-life clinical sub-
scales, highlighting the human cost of SCRD in schizo-
phrenia (Cohrs 2008; Goldman et al. 1996; Hofstetter et al.
2005). To reinforce this, schizophrenia patients often com-
ment that an improvement in sleep is one of their highest
priorities during treatment (Auslander and Jeste 2002).
Common brain mechanisms: an explanation
for the co-morbidity of SCRD and schizophrenia
Sleep and circadian rhythm disruption in schizophrenia
could be viewed as a side effect of antipsychotic medica-
tion, given that antipsychotic drugs, particularly typical
antipsychotics, have a severe sedative effect when taken at
high doses (Miller 2004). This seems unlikely, however, as
SCRD affects both medication-naı¨ve (Wulff et al. 2010)
and medicated patients (Krystal et al. 2008). Indeed, the
emergence of sleep disruption often precedes the diagnosis
of schizophrenia, occurring before any drugs have been
prescribed (Wulff et al. 2010). Recent data would suggest
that, if anything, antipsychotic drug treatment can actually
improve sleep quality in schizophrenia (Cohrs 2008; Kry-
stal et al. 2008). More specifically, schizophrenia patients
treated with typical antipsychotics show an increase in their









Fig. 1 Schematic illustration of the mechanisms underlying circadian
rhythm generation and sleep regulation. a Light detected by the eye is
relayed to the suprachiasmatic nuclei (SCN) in the hypothalamus via
the retinohypothalamic tract (RHT), which uses the neurotransmitters
glutamate and PACAP. Circadian rhythms are generated by a cell
autonomous transcriptional–translational feedback loop (TTFL)
involving a set of core clock genes. The molecular clock in the
SCN synchronises circadian clocks found in tissues throughout the
body, which regulate local physiology. b Sleep is the product of
multiple brain regions and neurotransmitters. Abbreviations for brain
regions: BF basal forebrain, DR/MR dorsal/medial raphe nucleus, LC
locus coeruleus, LDT laterodorsal tegmental nuclei, LH lateral
hypothalamus, LPT lateral pontine tegmentum, PPT pedunculopon-
tine tegmental nuclei, SCN suprachiasmatic nuclei, SLD sublatero-
dorsal nucleus, TMN tuberomammilary nucleus, VLPO ventrolateral
preoptic nuclei, vPAG ventral periaqueductal grey, vlPAG ventrolat-
eral periaqueductal grey. Abbreviations for neurotransmitters: 5-HT
serotonin, ACh acetylcholine, DA dopamine, GABA c-aminobutyric
acid, Gal galanin, Glut glutamate, His histamine, NA noradrenaline,
ORX orexin
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Social isolation, and the resulting absence of social
constraints, is also routinely suggested as a cause of SCRD
in schizophrenia. This hypothesis was recently addressed
by comparing the sleep patterns of schizophrenia patients
with those of unemployed healthy volunteers (Wulff et al.
2011). Severe SCRD was observed in schizophrenia, but
could not be attributed to an absence of routine, as major
sleep disruption was observed in schizophrenia patients
that followed a fixed routine. Conversely, undisturbed sleep
was seen in a number of control participants that did not
follow a fixed routine.
A more likely explanation for the co-morbidity of SCRD
and schizophrenia is the involvement of common brain
mechanisms. As described above, sleep is the product of a
complex interaction between multiple brain regions and
neurotransmitters. As a consequence, abnormalities in any
key neurotransmitter system will impinge upon sleep at
multiple levels. Similarly, schizophrenia is a disorder of
distributed brain circuits, affecting a range of neurotrans-
mitter systems (Weinberger and Harrison 2011), many of
which overlap with those involved in sleep regulation
(Wulff et al. 2010). Viewed in this context, it is no surprise
that SCRD is common in schizophrenia, or that SCRD will
in turn have widespread effects, ranging across many
aspects of neural, neuroendocrine and cognitive function
(Fig. 2).
Sleep and circadian rhythm disruption in schizophrenia
could also arise from dysfunction at any point in the cir-
cadian axis (i.e. input, oscillator or output). Such defects
would impact upon sleep via the circadian drive for
wakefulness, as appears to be the case in familial advanced
sleep phase syndrome (FASPS), which has previously been
linked to mutations in the clock gene Per2 (Toh et al.
2001).
Clinical evidence for common brain mechanisms
in SCRD and schizophrenia
Sleep and circadian rhythm disruption is rarely targeted for
treatment in schizophrenia, but when it is, patients report
improvements in both their sleep quality and psychiatric
symptoms (Kantrowitz et al. 2010). In a recent study,
insomnia was treated in 15 patients with persistent perse-
cutory delusions and schizophrenia (Myers et al. 2011).
Following a cognitive behavioural therapy (CBT) inter-
vention, there were significant reductions in both insomnia
and persecutory delusions. At least two-thirds of partici-
pants showed a substantial ([25 %) improvement in
insomnia, whilst approximately half showed a substantial
([25 %) reduction in persecutory delusions. There were
also reductions in levels of hallucinations, anxiety and
depression. Although consistent with the existence of
common mechanisms in SCRD and schizophrenia, the
results of this study should be interpreted with caution, due
to a number of methodological limitations; the sample size
was small, there was no control group, and 14 of the 15
patients received antipsychotic medication during the CBT
intervention.
Significantly, many of the pathologies caused by SCRD
are routinely reported as co-morbid with schizophrenia, but
are rarely linked to the disruption of sleep. For example,
sleep deprivation (Alhola and Polo-Kantola 2007; Chee
and Chuah 2008; Horne 1993; Van Dongen et al. 2003) and
Table 1 Impact of sleep and circadian rhythm disruption on emotional, cognitive and somatic responses
Emotional responses Cognitive responses Somatic responses
Fluctuations in mood (Banks and Dinges
2007; Oginska and Pokorski 2006; Scott
et al. 2006; Selvi et al. 2007)
Depression and psychosis (Johnson et al.
2006; Kahn-Greene et al. 2007; Riemann
and Voderholzer 2003; Sharma and
Mazmanian 2003)
Increased irritability, impulsivity and
frustration (Dahl and Lewin 2002; Kelman
1999; Muecke 2005)
Increased risk-taking (Acheson et al. 2007;
McKenna et al. 2007; O’Brien and Mindell
2005; Venkatraman et al. 2007)
Increased stimulant, sedative and alcohol
abuse (Baranski and Pigeau 1997; Boivin
et al. 2007; Killgore et al. 2006b; Roehrs and
Roth 2001a, b)
Impaired cognitive performance and ability to
multi-task (Dinges et al. 1997; Lamond et al.
2007; Pilcher and Huffcutt 1996)
Impaired memory, attention and concentration
(Chee and Chuah 2008; Dworak et al. 2007;
Goder et al. 2007; Oken et al. 2006)
Impaired communication and decision-making
skills (Baranski et al. 2007; Harrison and
Horne 2000; Killgore et al. 2006a; Killgore
et al. 2007; Lucidi et al. 2006)
Reduced creativity and productivity (Horne
1988; Jones and Harrison 2001; Killgore
et al. 2008; Randazzo et al. 1998)
Impaired motor performance (Kahol et al.
2008; Pilcher and Huffcutt 1996)
Dissociation (Lynn et al. 2012)
Drowsiness, micro-sleeps and unintended
sleep (Basner et al. 2008a, b; Philip and
Akerstedt 2006; Pilcher et al. 2000; Scott
et al. 2007).
Bodily sensations of pain and cold
(Kundermann et al. 2004; Landis et al. 1998;
Roehrs et al. 2006)
Increased risk of cancer (Davis and Mirick
2006; Hansen 2006)
Metabolic abnormalities, cardiovascular
disease and diabetes (Gangwisch et al. 2005;
Knutson et al. 2007; Laposky et al. 2008;
Maemura et al. 2007; Yang and Winkelman
2006; Young and Bray 2007)
Reduced immunity to disease and viral
infection (Irwin 2002; Lorton et al. 2006)
Altered regulation of the HPA axis (Meerlo
et al. 2008)
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circadian de-synchronisation (Kyriacou and Hastings 2010)
are known to impair cognition in healthy individuals, and
cognitive impairment is a core symptom of schizophrenia.
Thus, cognitive impairments in schizophrenia could be
exacerbated by circadian de-synchronisation and/or dis-
turbed sleep. Consistent with this, associations between
sleep and cognitive performance have been reported in
medication-naı¨ve (Forest et al. 2007), medicated (Bro-
mundt et al. 2011; Goder et al. 2004, 2008; Wulff and
Joyce 2011), and unmedicated schizophrenia patients
(Yang and Winkelman 2006). In the latter study, the
severity of patients’ cognitive symptoms was inversely
related with slow-wave sleep duration and REM sleep
density (Yang and Winkelman 2006).
Memory consolidation is just one cognitive function that
warrants further investigation. Memory impairment is
prevalent in schizophrenia (Aleman et al. 1999), and it has
been suggested that sleep makes a crucial contribution to
memory consolidation (Stickgold 2005). Reduced over-
night consolidation of procedural learning has been dem-
onstrated in schizophrenia patients (Manoach et al. 2004),
and more recently, this effect was linked to a reduction in
slow-wave sleep duration (Manoach et al. 2010). The
negative symptoms of schizophrenia might also be sensi-
tive to SCRD, since circadian de-synchronisation increases
negative mood, irritability and affective volatility in heal-
thy volunteers (Kyriacou and Hastings 2010; Murray and
Harvey 2010). Consistent with this, improvements in sleep
quality are frequently correlated with the amelioration of
negative symptoms in schizophrenia patients (Hofstetter
et al. 2005; Yamashita et al. 2004).
Using animal models to establish mechanistic links
between SCRD and schizophrenia
Animal models provide essential tools to understand the
mechanisms underlying neuropathological processes,
enabling highly controlled genetic, anatomical, physio-
logical and behavioural studies that are not possible in
humans. If, as our central hypothesis proposes, common
mechanisms are involved in the pathogenesis of SCRD and
schizophrenia, then SCRD should be observed in schizo-
phrenia-relevant animal models. Conversely, animal models
of SCRD may display schizophrenia-relevant behavioural
and neurobiological abnormalities. There is a rapidly
accumulating body of evidence which supports the first of
these predictions, while the second prediction has yet to be
tested.
SCRD in schizophrenia-relevant mouse models:
existing evidence
The hypotheses outlined above apply to genetic, pharma-
cological and environmental models, and are not species-
specific. For the sake of brevity, this paper focuses on
schizophrenia-relevant transgenic mouse models. Sleep
and circadian function has yet to be investigated in any
pharmacological or environmental mouse models, but this
represents a promising avenue for future research; it would
be particularly interesting to see whether sleep is affected
in the PCP, MK-801 and ketamine models of schizophre-
nia. It should also be noted that SCRD has already been
demonstrated in two schizophrenia-relevant transgenic
Drosophila models (Sawamura et al. 2008; Zheng and
Sehgal 2010).
Fig. 2 The key components in the regulation and maintenance of the
sleep/wake cycle and its relationship to mood/cognition and mental
health. The sleep/wake cycle is regulated directly by (i) The 24-h
body clock/circadian clock located within the suprachiasmatic nuclei
(SCN), (ii) wake-dependent homeostatic drivers (e.g. adenosine) that
build-up and generate ‘‘sleep pressure’’, (iii) social behaviours that
force a sleep/wake pattern on the individual. The SCN drives
wakefulness throughout the day and sleep during the night. This 24-h
rhythm interacts with the homeostatic ‘‘hourglass oscillator’’ produc-
ing increased sleep pressure during wake and its dissipation during
sleep. The circadian system directly regulates multiple neurotrans-
mitter and brain systems that either drive or modulate sleep, including
the hypothalamo–pituitary–adrenal axis (HPA) and melatonin from
the pineal gland. The SCN also coordinates the 24-h biology of
peripheral oscillators, maintaining internal synchrony of 24-h biolog-
ical timing processes. A mismatch between central and peripheral
oscillators (internal desynchrony), as occurs in shift work or jet-lag, is
associated with mood imbalance and depression. All of the compo-
nents within the triangle are modulated by light, which acts to: entrain
the circadian pacemaker to the light/dark cycle; alter melatonin
production from the pineal gland; modulate the HPA axis; and elevate
or suppress levels of mood and cognition. Social behaviours will also
change an individual’s exposure to the light/dark cycle (Mistlberger
and Skene 2004), and have a major effect on mood/cognition and
mental health. The quality of sleep and the stability of the sleep/wake
cycle have a direct effect upon mood, cognitive processing and
mental health (Table 1)
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A number of genes have been linked with schizophrenia,
and endophenotypes thereof, through a combination of
genetic linkage studies, genome-wide association studies
and appraisals of biological plausibility. Those most
established in the ‘candidate gene’ literature are Nrg1
(Harrison and Law 2006; Mei and Xiong 2008; Stefansson
et al. 2002), Akt1 (Arguello and Gogos 2008), Disc1
(Brandon and Sawa 2011; Johnstone et al. 2011), Grm3
(Harrison et al. 2008), Dao (Chumakov et al. 2002; Verrall
et al. 2010), Comt (Tunbridge et al. 2006), Dtnbp1 (Wil-
liams et al. 2005) and ErbB4 (Mei and Xiong 2008). More
recent additions to the literature include Snap-25 (Corra-
dini et al. 2009), Vipr2 (Vacic et al. 2011), Cckar (Koefoed
et al. 2009), Gsk3b (Lipina et al. 2012), Pde4d (Fatemi
et al. 2008; Numata et al. 2008; Tomppo et al. 2009), Tcf4
(Brzozka et al. 2010), MIR137 (Ripke et al. 2011) and
ZNF804A (O’Donovan et al. 2008). To the best of our
knowledge, sleep and circadian function has only been
evaluated in knockout or mutant models of four of these
genes, namely Snap-25 (Oliver et al. 2012), Vipr2 (Hughes
and Piggins 2008), Nrg1 (Johnson et al. 2002) and Cckar
(Shimazoe et al. 2008). In all four cases, significant SCRD
was observed, as outlined below.
When circadian disruption is observed in a mouse
model, it is important to identify the level of the circadian
system at which this disturbance arises (Fig. 3). Does the
deficit affect inputs to the SCN, the function of the SCN
itself, or the physiological outputs of the SCN? Such
knowledge is vital, as it will inform the selection and/or
development of the most appropriate therapeutic inter-
vention. To date, this approach has only been implemented
in the Snap-25 (Oliver et al. 2012) and Vipr2 models
(Hughes and Piggins 2008).
How can one determine the level at which circadian
disturbances arise? Light input to the SCN can be evaluated
by measuring circadian and molecular responses to light
(e.g. phase shifting, entrainment, negative masking and
clock gene induction) (Albrecht and Foster 2002; Jud et al.
2005), whilst core oscillator function can be assessed at a
behavioural level via activity rhythms under constant
conditions, and at a cellular level using clock-gene reporter
assays (e.g. Per2::Luc) (Savelyev et al. 2011). Clock out-
puts can be determined from hormonal rhythms, and from
gene expression and reporter assays in peripheral tissues.
For example, hormones such as corticosterone can be
monitored with real-time measurements from faeces
(Abraham et al. 2006). Finally, sleep/wake behaviour can
be assessed using non-invasive methods such as video
tracking (Fisher et al. 2012).
Snap-25 (blind-drunk mutant)
Previous work has shown that the blind-drunk (Bdr) mouse,
a model of Snap-25 exocytotic disruption, displays
schizophrenia-related endophenotypes that are modulated
by environmental stress (Jeans et al. 2007; Oliver and
Davies 2009). Bdr mutants also show disturbances in cir-
cadian organisation that appear to specifically affect out-
puts of the SCN (Fig. 4). The rest/activity rhythms of Bdr
mice are phase advanced and fragmented under a light/dark
cycle. Retinal inputs appear normal in Bdr mice, as light-
induced phase shifts, masking, pupil constriction and reti-
nal histology are all unaffected. Similarly, clock gene
rhythms within the SCN are normally phased both in vitro
and in vivo. However, the 24-h rhythms of arginine vaso-
pressin (Avp) within the SCN and plasma corticosterone
Fig. 3 Suggested model of the
mechanistic links between
cognitive and circadian
disturbances. We propose the
evaluation of both
schizophrenia-relevant models
and models of circadian
disruption, to confirm whether
defects at one level are
associated with defects at the
other. Similarly, therapeutic
interventions that correct
defects at one level should
produce concomitant
improvements at the other
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are both markedly phase-advanced in Bdr mice. These data
suggest that the circadian phenotype of the Bdr mouse
arises from a disruption of synaptic connectivity within the
SCN that alters critical output signals (Oliver et al. 2012).
Vipr2
Recent studies have shown that Vipr2 duplications confer a
significant risk for schizophrenia (Vacic et al. 2011).
Vasoactive intestinal polypeptide (Vip) and its receptor,
Vipr2 (VPAC2), play a critical role within the SCN. Real-
time imaging of circadian gene expression in SCN slices
has shown that the VPAC2 receptor is required for the
maintenance of circadian oscillations within SCN neurons,
and for the synchronisation of oscillations between these
neurons (Maywood et al. 2006). Vipr2 knockout mice
demonstrate circadian abnormalities, including a shortened
circadian period of approximately 22 h (Hughes and Pig-
gins 2008). The deficit in these mice must reside in the
SCN itself or in its outputs, as light input to the SCN
appears relatively normal; exposure to light increases
phosphoprotein and immediate early gene expression in the
Vipr2-/- SCN, whilst a subset of Vipr2-/- mice respond
appropriately to nocturnal light pulses, displaying robust
phase-shift responses.
Nrg1
Neuregulin 1 (NRG1) is a growth factor involved in neu-
rodevelopment and plasticity, which has been associated
with both schizophrenia (Harrison and Law 2006; Mei and
Xiong 2008; Stefansson et al. 2002) and schizotypal per-
sonality disorder (Lin et al. 2005). There is some evidence
that its expression is increased in the brains of
schizophrenia patients (Harrison and Law 2006; Hashimoto
et al. 2004). Mice heterozygous for a disruption in the Nrg1
gene show disrupted rest/activity rhythms (Johnson et al.
2002), whilst wheel-running activity is inhibited by the
long-term infusion of NRG1 into the third ventricle of the
hamster brain (Snodgrass-Belt et al. 2005). NRG1 is
expressed in the SCN and retinal ganglion cells (Bernstein
et al. 2006; Sharif et al. 2009), consistent with its proposed
involvement in circadian function.
Cckar
The Cholecystokinin A receptor (CCK-AR) is a G-protein
coupled receptor that binds the neuropeptide cholecysto-
kinin (CCK) (Noble et al. 1999). Abnormal levels of CCK
mRNA have been observed in the brains of schizophrenia
patients (Bachus et al. 1997; Zachrisson et al. 1999), while
several studies have reported an association between the
Cckar gene and schizophrenia (Koefoed et al. 2009; Tac-
hikawa et al. 2000, 2001; Toirac et al. 2007; Wei and
Hemmings 1999). Dopamine may mediate the relationship
between CCK and schizophrenia, as CCK-ARs modulate
CCK-stimulated dopamine release in the mesolimbic sys-
tem (Marshall et al. 1991). There is also evidence that CCK
plays a role in sleep regulation. The intraperitoneal
administration of CCK promotes slow-wave sleep and
inhibits locomotor activity in rats (Kapas et al. 1988). CCK
may exert its effects through orexin, a neurotransmitter
known to influence wakefulness, as CCK activates orexin
neurons by binding to CCK-ARs (Tsujino et al. 2005).
CCK-ARs are also involved in photoentrainment; light-
induced phase shifts are significantly attenuated in Cckar
knockout mice, as is light-induced clock gene expression in
the SCN (Shimazoe et al. 2008).
Fig. 4 Summary of findings in the blind-drunk (Bdr) mouse model of
Snap-25 exocytotic disruption. The rest/activity rhythms of Bdr mice
are phase advanced and fragmented under a light/dark cycle,
reminiscent of the disturbed sleep/wake patterns observed in schizo-
phrenia. Retinal inputs appear normal in mutants, and clock gene
rhythms within the suprachiasmatic nuclei (SCN) [e.g. Per2 and
vasoactive intestinal peptide (Vip)] are normally phased both in vitro
and in vivo. However, the 24-h rhythms of arginine vasopressin (Avp)
within the SCN and plasma corticosterone are both markedly phase
advanced in Bdr mice. We suggest that the Bdr sleep/wake phenotype
arises from a disruption of synaptic connectivity within the SCN that
alters critical output signals (Oliver et al. 2012). Abbreviations for
brain regions: DMH dorsomedial hypothalamus, sPVZ subparaven-
tricular zone
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SCRD in schizophrenia-relevant mouse models:
future studies
The preceding section describes four schizophrenia-relevant
mouse models with significant sleep and circadian deficits.
The challenge for the future is to identify more of these
models and to characterise them fully. Characterisation
entails screening for both SCRD and schizophrenia-relevant
behaviours; the models mentioned above are only described
as ‘schizophrenia-relevant’ by virtue of the fact that the genes
in question share a significant association with schizophrenia
(or in the case of Snap-25, a plausible biological connection).
Which of these mice provides the best model of schizophrenia
remains to be seen. The Bdr mutant (Jeans et al. 2007; Oliver
and Davies 2009) and NRG1type 1-tg mouse (Deakin et al.
2009) share some features in common with the disorder,
while the Vipr2 and Cckar knockout models have not been
extensively tested from a behavioural perspective. To redress
this balance, a variety of tests could be employed across a
range of behavioural domains (Chadman et al. 2009), as
described in ‘‘Challenges associated with modelling schizo-
phrenia in rodents’’. In the paragraphs that follow, we con-
sider four more genes with the potential to link schizophrenia
with sleep and circadian function.
ErbB4
NRG1 (see ‘‘SCRD in schizophrenia-relevant mouse
models: existing evidence’’) acts through the same family
of tyrosine kinase receptors as TGF-a, a putative inhibitory
output signal of the SCN (Kramer et al. 2001). TGF-a acts
on ERBB1 receptors, whilst NRG1 acts on ERBB4
receptors. ERBB1 receptors have a known role in loco-
motor activity and sleep; mice with reduced ERBB1
receptor activity show reduced negative masking by light
(Kramer et al. 2001). Future studies should address whether
ERBB4 receptors play a similar role. Polymorphisms in
ErbB4 have previously been associated with schizophrenia
(Mei and Xiong 2008).
Gsk3b
GSK3 is a serine/threonine protein kinase, whose deregu-
lation has been implicated in schizophrenia and bipolar
disorder (Lipina et al. 2012). GSK3 activity is inhibited by
the putative schizophrenia risk genes Disc1 and Akt1
(Bradshaw and Porteous 2012; Lipina et al. 2012). Sig-
nificantly, the GSK3 inhibitor TDZD-8 ameliorates
hyperactivity and prepulse inhibition (PPI) deficits in the
Disc1-L100P mutant, a mouse model of schizophrenia
(Lipina et al. 2012). In the Disc1-Q31L mutant mouse, a
model of depression, TDZD-8 corrects a PPI deficit,
reduces immobility in the forced swim test, and increases
social interaction (Lipina et al. 2012). Interestingly, clini-
cians often prescribe the mood stabiliser lithium (a GSK3
inhibitor) to schizophrenia patients to augment their anti-
psychotic medication, although the efficacy of this strategy
is unclear (Leucht et al. 2004). GSK3b has a known role in
circadian function; it phosphorylates clock proteins and
regulates several components of the transcriptional–trans-
lational feedback loop that generates circadian rhythms
(Cross et al. 1995; Iitaka et al. 2005; Martinek et al. 2001;
Yin et al. 2006). GSK3b also inhibits CREB DNA-binding
activity (Grimes and Jope 2001), which is involved in
circadian signal transduction (Lee et al. 2010).
Pde4d
PDE4 is a phosphodiesterase that been associated with
schizophrenia in a number of studies (Fatemi et al. 2008;
Numata et al. 2008; Tomppo et al. 2009). Like GSK3,
PDE4 activity is inhibited by the putative schizophrenia
risk gene Disc1 (Bradshaw and Porteous 2012; Lipina et al.
2012). Crucially, the PDE4 inhibitor Rolipram acts as a
cognitive enhancer, facilitating long-term potentiation,
memory performance and latent inhibition in wildtype
rodents (Barad et al. 1998; Davis and Gould 2005; Zhang
et al. 2004), and attenuating PPI deficits in the Disc1-L100P
mutant model of schizophrenia (Lipina et al. 2012). In
addition, Rolipram has antidepressant-like properties,
reducing immobility in the forced swim test in wildtype rats
(Zhang et al. 2006). From a circadian perspective, PDE4
regulates cAMP signalling, which is involved in circadian
signal transduction (O’Neill and Reddy 2012). Intriguingly,
a polymorphism in Pde4d has been associated with sleepi-
ness in healthy individuals (Gottlieb et al. 2007).
Tcf4
Several large genome-wide association studies have iden-
tified the basic helix-loop-helix (bHLH) transcription fac-
tor TCF4 as one of the most significant schizophrenia
susceptibility genes (Brzozka et al. 2010). The protein
encoded by this gene resembles ID (inhibitor of DNA-
binding) proteins, which act as negative regulators of the
transcriptional–translational feedback loop that generates
intracellular circadian rhythms (Duffield et al. 2009). To
date, at least eight different Tcf4 mutants have been pro-
duced by ENU mutagenesis, but their circadian profiles
have yet to be characterised.
Schizophrenia-relevant abnormalities in mouse models
of SCRD
To establish mechanistic links between SCRD and
schizophrenia, a parallel approach is to screen mouse
Schizophrenia and SCRD 1067
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models of circadian disruption for schizophrenia-relevant
behaviours, such as impaired cognitive function. To our
knowledge, the Clock mutant, described below, is the only
mouse model of SCRD which has been studied in this way
(Roybal et al. 2007). The Clock mutant does not show any
schizophrenia-relevant behaviours, but has a striking
mania-like phenotype, which can be reversed with the
mood stabiliser lithium (Roybal et al. 2007). Future
research will reveal whether other mouse models of SCRD
have a schizophrenia-relevant phenotype.
Clock (Clock mutant)
The Clock mutant was first identified in 1994 from a cir-
cadian screen of ENU mutants (Vitaterna et al. 1994).
These animals have an extended circadian period (Vita-
terna et al. 1994), and sleep significantly less than wild-
types (Naylor et al. 2000), consistent with the decreased
need for sleep observed in patients with mania (Plante and
Winkelman 2008). Their behavioural profile is also remi-
niscent of bipolar patients in the manic state; they show
hyperactivity, excessive-reward seeking behaviour [as
measured by intracranial self-stimulation (ICSS), cocaine
preference and sucrose preference], reduced depression
like-behaviour (as measured with the Porsolt forced swim
test and learned helplessness test), reduced anxiety-like
behaviour (as measured with the open field test and ele-
vated plus maze) (Roybal et al. 2007) and increased
exploratory behaviour (Easton et al. 2003).
Therapeutic interventions in mouse models
with simultaneous deficits
Once models that display simultaneous circadian and
schizophrenia-relevant abnormalities have been identified,
therapeutic interventions can be introduced. If schizo-
phrenia and SCRD share a common mechanistic origin,
then two further predictions logically follow. The
administration of drugs used to treat schizophrenia (e.g.
antipsychotics and mood-stabilisers) should produce a
concurrent improvement in the animals’ SCRD and
schizophrenia-relevant deficits, while therapies that target
SCRD should do likewise (Fig. 3). The latter approach
could involve either pharmacological (e.g. melatonin
administration) or environmental interventions (e.g.
modification of the light/dark cycle or scheduled volun-
tary exercise) (Power et al. 2010). This type of experi-
ment has never been performed in a schizophrenia-
relevant animal model, although the pharmacological
imposition of sleep has been shown to slow cognitive
decline in a transgenic mouse model of Huntington’s
disease (Pallier et al. 2007).
Challenges associated with modelling schizophrenia
in rodents
Animal studies afford a level of control that is simply not
possible in human studies. Human participants differ from
each other in all manner of dimensions, including their age,
education, medication history, genetic makeup and life
experiences. In this context, it is difficult to attribute a
specific behavioural observation (e.g. disturbed sleep) to a
specific underlying trait (e.g. the possession of a particular
risk-conferring gene). In animal studies, there are relatively
fewer confounds, so making such attributions is more
straightforward. Genetic manipulation is also possible in
rodents, enabling the investigator to move beyond corre-
lation and infer causality.
Modelling schizophrenia in animals raises a number of
complex theoretical and experimental design issues for the
investigator (for reviews, see Arguello and Gogos 2010;
Harrison et al. 2012; Nestler and Hyman 2010; Papaleo
et al. 2012). The first and perhaps biggest challenge is the
process of selecting which gene to manipulate. Despite
years of research, no gene has been unequivocally estab-
lished as conferring increased susceptibility to schizo-
phrenia (Crow 2008). The literature is littered with genes
that have yielded positive results in one or two genetic
association studies, only for several follow-up studies to
draw a blank (Crow 2008). A ‘schizophrenia model’ is only
as good as the evidence linking the gene in question with
the disorder itself, and from this perspective, the validity of
almost any model can be questioned. The likely explana-
tion for these results is that schizophrenia is caused by a
large number of genes, each one having a very small effect
(Chakravarti 1999). Put simply, no single gene is either
necessary or sufficient to cause the disorder. In light of this,
the value of single gene models is debatable. Double- or
triple-gene models may be more realistic, but these are
more complex and costly to produce. A further limitation is
that some schizophrenia risk genes (e.g. G72/DAOA) have
no known ortholog in rodents (Chumakov et al. 2002).
Besides choosing which gene to manipulate, the inves-
tigator must decide how to manipulate it. Knockout models
are the simplest and therefore the most common, but again,
are unlikely to represent schizophrenia that faithfully.
There is no evidence for null mutations in schizophrenia,
but there is evidence for the up- or down-regulation of
specific genes (Harrison and Weinberger 2005). In this
context, transgenic over-expression or heterozygous
knockout may prove more suitable tools for modelling
schizophrenia. The investigator must also decide whether
the genetic manipulation is constitutive or conditional.
Most models are constitutive; that is, the manipulation is
present throughout the brain and throughout the animal’s
lifetime. Given evidence that brain abnormalities in
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schizophrenia are more pronounced in some brain areas
than others, and that they can develop over time (Ellison-
Wright et al. 2008), the constitutive approach may not be
the most appropriate. Conditional models, in which the
timing and location of the manipulation are more tightly
regulated, provide a more flexible alternative.
Another complication is the not inconsiderable variation
amongst patients labelled with schizophrenia. The disorder
is associated with a wide range of symptoms, and two
patients with the same diagnosis may present a very dif-
ferent subset of these symptoms (Andreasen 1999). Thus,
treating a condition as complex as schizophrenia as a
unitary disorder could be a mistake. Perhaps a more
appropriate approach would be to model specific symptoms
(or endophenotypes) in isolation (Kaffman and Krystal
2012).
In rodents, some schizophrenia-relevant behaviours are
easier to model than others. Schizophrenia is characterised
by positive symptoms (e.g. hallucinations and delusions),
negative symptoms (e.g. avolition and anhedonia) and
cognitive symptoms (e.g. impaired working memory, sen-
sorimotor gating and attentional set-shifting) (Andreasen
1995; Elvevag and Goldberg 2000). In humans, halluci-
nations and delusions are only revealed through patients’
verbal reports, so these symptoms are difficult to investi-
gate in rodents. Nonetheless, hyperlocomotion and stereo-
typic behaviours are considered by many to reflect the
positive symptoms of schizophrenia (Nilsson et al. 1997;
Sams-Dodd 1996). Similarly, reduced social interaction in
rodents is often presented as a direct analogue of the
negative symptoms witnessed in schizophrenia (Lee et al.
2005; Sams-Dodd 1996). Whether these behaviours are
conceptually and neurally equivalent seems highly unli-
kely, however (Bussey et al. 2012; Garner et al. 2006). In
contrast, the human and rodent versions of most cognitive
tasks are at least superficially similar. PPI, for example, is a
measure of sensorimotor gating which can be tested almost
identically in humans and rodents (Swerdlow et al. 2008),
while the attentional set-shifting task, which measures
cognitive flexibility, is modelled directly on its human
counterpart, the Wisconsin Card Sorting Test (Bissonette
and Powell 2012; Garner et al. 2006). Questions remain as
to the suitability of set-shifting tasks for mice, however
(Garner et al. 2006). Working memory is also routinely
tested in rodents, although again, it is unclear whether the
human and rodent versions of these tasks tap the same
neural substrates (Sanderson and Bannerman 2010).
Of course, behavioural assessment is not the only way to
assess the validity of schizophrenia-relevant models.
Investigators can also look for neurophysiological changes
reminiscent of those observed in schizophrenia. These
include structural changes, such as reduction of cortical
thickness and enlargement of the lateral ventricles
(Weinberger et al. 1982), and characteristic changes in
neurotransmitter systems, such as glutamatergic hypo-
function (Konradi and Heckers 2003).
To summarise, it would be a significant overstatement to
suggest that schizophrenia can be faithfully modelled in
rodents. First, some of the core symptoms of schizophrenia
simply cannot be measured in rats or mice, as explained
above. Secondly, schizophrenia is a multi-gene disorder, so
it seems improbable that a single-gene model could ever
demonstrate the full range of symptoms observed in a
patient. Finally, there are notable neuroanatomical differ-
ences between humans and rodents; the prefrontal cortex,
for example, is far more developed in humans than it is in
rodents. Despite these limitations, murine models may still
yield valuable insights into the roles of schizophrenia risk
genes in brain function, such as whether they contribute to
sleep and circadian function.
Challenges associated with sleep and circadian
phenotyping in rodents
Sleep and circadian rhythms in humans and rodents are not
identical, not least as rodents are nocturnal and humans
diurnal. In addition, humans typically sleep once every
24 h, whereas rodents tend to alternate between several
bouts of sleep and wakefulness (Fisher et al. 2012). As a
result, the sleep and circadian phenotype of a rodent model
may not translate directly to humans. In addition, envi-
ronmental light intensity varies continuously in the natural
world, whereas most experimental paradigms employ a
discrete transition from light to dark and vice versa.
The way we assess the circadian/sleep phenotype of
rodents might also cause problems. Crucially, locomotor
activity is the dependent variable in most circadian
screening paradigms, and locomotor activity is subject to
all manner of influences besides circadian function,
including basic motor function, anxiety and arousal levels.
Therefore, this approach might not be the most appropriate
for assessing mouse models with locomotor deficits, such
as the schizophrenia-relevant NRG1type 1-tg mouse (Deakin
et al. 2009). An obesity phenotype, as seen in Clock mutant
mice, could also complicate behavioural phenotyping
(Turek et al. 2005). Invasive measures of circadian func-
tion (e.g. clock gene rhythms within the SCN) provide a
useful alternative, as they are not subject to the same
confounds.
Differences in mouse strain must also be taken into
consideration. For example, the circadian system of the
C57/BL6 mouse is more sensitive to light than that of the
C3H mouse. Hence, C57/BL6 mice are able to entrain their
circadian behaviour at much lower irradiances (Foster and
Helfrich-Forster 2001). There is also evidence that pineal
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melatonin content varies between mouse strains (Ebihara
et al. 1986; Goto et al. 1989). In contrast to wild mice,
several inbred strains, including the C57/BL6 mouse, do
not have detectable melatonin levels in their pineal glands.
Conclusion and future directions
Sleep and circadian rhythm disruption and schizophrenia are
often co-morbid, and this co-morbidity may arise from the
involvement of common brain mechanisms. SCRD in
schizophrenia is not merely a side effect of antipsychotic
medication, nor is it a by-product of an absence of social
routine. The treatment of insomnia in schizophrenia patients
produces a concomitant improvement in psychiatric symp-
toms, which provides further support for the hypothesis that
common mechanisms are involved. Moreover, many
symptoms associated with SCRD, such as impaired cogni-
tive performance, are frequently observed in schizophrenia
patients. Animal models provide a means to test our
hypothesis of mechanistic overlap. Implicit in our theory are
four key predictions that can be tested in rodents:
1. Sleep and circadian rhythm disruption should be
observed in schizophrenia-relevant models.
2. Schizophrenia-relevant behavioural abnormalities (e.g.
cognitive impairments) may be observed in models of
SCRD.
3. Therapies that target SCRD (e.g. melatonin or sched-
uled voluntary exercise) should ameliorate both SCRD
and schizophrenia-relevant behavioural abnormalities
in models which display simultaneous deficits.
4. Therapies that target schizophrenia-relevant behav-
ioural abnormalities (e.g. antipsychotic or mood-
stabilising drugs) should do likewise.
In this review, we have drawn attention to several
schizophrenia-relevant mouse models which show signifi-
cant sleep and circadian deficits. The challenge for the
future is to identify more of these models, characterise
them fully, and investigate their responses to therapeutic
interventions. Given the continued interest in, and avail-
ability of, schizophrenia-relevant mouse models, the eval-
uation of circadian and sleep physiology and behaviour in
these models represents an excellent opportunity to better
understand the shared mechanistic basis of SCRD and
schizophrenia.
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